Tags : Luspatercept

BMS’s Reblozyl (luspatercept) Receives Health Canada Approval for Beta Thalassemia

Shots:   The approval is based on the P-lll BELIEVE study assessing Reblozyl (luspatercept) + BSC vs PBO + BSC in adult patients with anemia associated with beta-thalassemia requiring regular RBC transfusions Result: ≥33% reduction in RBC transfusion with a reduction of ≥2units from 13-24wks. (21.4% vs. 4.5%), results were published in NEJM Reblozyl regulate late-stage […]Read More

Celgene and Acceleron Pharma Submit Biologics License Application (BLA) to

Shots: The BLA submission is based on P-III MEDALIST & BELIEVE studies. The P-III MEDALIST study involves assessing of luspatercept (1.0 mg/kg) vs PBO in 229 patients with low to intermediate risk myelodysplastic syndromes (MDS)-associated anemia + RBC transfusion aged ~71yrs across 11 countries The P-III BELIEVE study involves assessing of luspatercept (1.0 mg/kg) + […]Read More